IMMUCELL CORP /DE/ 8-K

What Happened
ImmuCell Corporation (ICCC) filed an 8-K on May 8, 2026 reporting that it and Norbrook Laboratories Limited (Northern Ireland) entered into a Settlement Deed to resolve and release all claims arising from their 2019 Development Services and Commercial Supply Agreement. Under the deed, Norbrook agreed to pay ImmuCell $2,000,000. The underlying agreement expired March 31, 2026. The settlement is governed by Northern Ireland law, includes confidentiality undertakings, and states that neither party admits liability.

Key Details

• Parties: ImmuCell Corporation and Norbrook Laboratories Limited (incorporated in Northern Ireland).
• Date filed/entered: Settlement Deed dated and filed May 8, 2026.
• Payment: Norbrook to pay ImmuCell $2,000,000.
• Contract background: Resolves claims arising from a 2019 Development Services and Commercial Supply Agreement that expired March 31, 2026; settlement contains confidentiality terms and no admission of wrongdoing.

Why It Matters
The agreement provides ImmuCell a one-time $2.0M payment and closes a long-running commercial dispute tied to the 2019 agreement, removing related claims and uncertainty. For investors, this may mean a cash inflow and reduced legal risk; monitor ImmuCell’s subsequent filings for timing of receipt, accounting treatment, and any impact to reported results. The confidentiality provisions limit public details about the dispute and resolution.